Division of Population and Behavioural Sciences, School of Medicine, University of Saint Andrews, Saint Andrews, UK.
Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
BMJ Open. 2020 Jun 3;10(6):e033424. doi: 10.1136/bmjopen-2019-033424.
Urinary tract infections (UTIs) are the second most common type of infection worldwide, accounting for a large number of primary care consultations and antibiotic prescribing. Current diagnosis is based on an empirical approach, relying on symptoms and occasional use of urine dipsticks. The diagnostic reference standard is still urine culture, although it is not routinely recommended for uncomplicated UTIs in the community, due to time to diagnosis (48 hours). Faster point-of-care tests have been developed, but their diagnostic accuracy has not been compared. Our objective is to systematically review and meta-analyse the diagnostic accuracy of currently available point-of-care tests for UTIs.
Studies evaluating the diagnostic accuracy of point-of-care tests for UTIs will be included. PubMed, Web of Science, Embase and Cochrane Database of Systematic Reviews were searched from inception to 1 June 2019. Data extraction and risk-of-bias assessment will be assessed using the Quality Assessment of Diagnostic Accuracy Studies tool. Meta-analysis will be performed depending on data availability and heterogeneity.
This is a systematic review protocol and therefore formal ethical approval is not required, as no primary, identifiable, personal data will be collected. Patients or the public were not involved in the design of our research. However, the findings from this review will be shared with key stakeholders, including patient groups, clinicians and guideline developers, and will also be presented and national and international conferences.
CRD42018112019.
尿路感染（UTIs）是全球第二大常见感染类型，占初级保健咨询和抗生素处方的很大比例。目前的诊断基于经验方法，依赖于症状和偶尔使用尿液试纸。诊断参考标准仍然是尿液培养，但由于诊断时间（48 小时），它不常规推荐用于社区中的简单尿路感染。已经开发出更快的即时检测方法，但尚未比较其诊断准确性。我们的目标是系统地回顾和荟萃分析目前可用于尿路感染的即时检测方法的诊断准确性。
将纳入评估即时检测尿路感染诊断准确性的研究。从开始到 2019 年 6 月 1 日，将在 PubMed、Web of Science、Embase 和 Cochrane 系统评价数据库中进行搜索。使用诊断准确性研究质量评估工具评估数据提取和偏倚风险评估。将根据数据可用性和异质性进行荟萃分析。
这是一项系统评价方案，因此不需要正式的伦理批准，因为不会收集原始的、可识别的、个人数据。患者或公众未参与我们研究的设计。然而，这项综述的结果将与主要利益相关者分享，包括患者群体、临床医生和指南制定者，并将在国家和国际会议上展示。
PROSPERO 注册号：CRD42018112019。
